Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

Eligibility criteria:
Inclusion Criteria:

          -  Subjects aged between 18 to 70 years,

          -  Patients with symptoms and complaints consistent with possible or confirmed COVID- 19
             observed within the last 5 days,

          -  Patients with uncomplicated possible or confirmed COVID-19:

               1. Symptoms such as fever, muscle aches, joint pain, cough, sore throat, nasal
                  congestion, however no respiratory distress, no tachypnea or no SpO2 < 93%,

               2. Chest imaging (X-ray or CT chest) documented as normal

          -  Patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia
             symptoms):

               1. Symptoms such as fever, muscle aches, joint pain, cough, sore throat, nasal
                  congestion, as well as respiratory rate <30/min and SpO2 above 93% on room air,

               2. Chest imaging (X-ray or CT chest)-documented mild pneumonia symptoms

          -  Patients who were decided to isolate and treat because of COVID-19 in the hospital,

          -  Patients who have not been involved in any other interventional studies.

        Exclusion Criteria:

          -  Patients considered as inappropriate for this study for any reason like noncompliance
             by the researcher,

          -  Patients with persisting refractory nausea, vomiting, chronic diarrhoea or chronic
             gastrointestinal disorders, inability to swallow the study drug which may affect
             adequate absorption,

          -  Patients with chronic liver disease: alanine aminotransferase (ALT)/aspartate
             aminotransferase (AST) elevated over 5 times the upper limit of normal (ULN),

          -  Patients with gout or hyperuricemia (above the ULN),

          -  Patients with severe pneumonia symptoms,

          -  Patients with known allergy to Favipiravir or for substances used in the study,

          -  Patients did not receive specific antiviral drugs such as lopinavir/ritonavir,
             ribavirin, arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal
             antibodies within one week before admission.

          -  Patients with known chronic renal impairment/failure [creatinine clearance (CcCl) <30
             mL/min],

          -  Pregnant and lactating women

          -  Patients undergoing cardiac ablation therapy

          -  Patients using antiarrhythmic drugs

          -  Patients actively receiving chemotherapy

          -  Acute immunosuppressed patients

          -  Patients undergoing psychosis therapy
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 70 Years

Eligibility (NLI label): Entailment